Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

3.6%

2 terminated/withdrawn out of 56 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

27%

15 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
22(44.9%)
Phase 3
15(30.6%)
N/A
10(20.4%)
Phase 1
2(4.1%)
49Total
Phase 2(22)
Phase 3(15)
N/A(10)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (56)

Showing 20 of 56 trials
NCT05735977Not ApplicableCompleted

Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared

Role: collaborator

NCT05425043Not ApplicableRecruiting

Granulocyte Transfusions After Umbilical Cord Blood Transplant

Role: collaborator

NCT00002757Phase 3Completed

TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

Role: collaborator

NCT00020566Phase 3Unknown

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Role: collaborator

NCT00047138Phase 3Unknown

Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

Role: collaborator

NCT00025441Phase 2Completed

Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors

Role: collaborator

NCT00025428Phase 3Completed

Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma

Role: collaborator

NCT00349024Not ApplicableUnknown

Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer

Role: lead

NCT00683319Active Not Recruiting

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Role: lead

NCT00416559Phase 2Unknown

Observation of Young Patients With Localized Neuroblastoma Who Have Undergone Surgery Only

Role: lead

NCT00360854Phase 1Unknown

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

Role: lead

NCT00281905Phase 2Unknown

Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors

Role: lead

NCT00313521Phase 2Unknown

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

Role: lead

NCT00278239Unknown

Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors

Role: lead

NCT00287950Not ApplicableUnknown

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Role: lead

NCT00360750Not ApplicableUnknown

Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye

Role: lead

NCT00287976Phase 2Unknown

Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma

Role: lead

NCT00293358Phase 3Completed

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

Role: lead

NCT00392340Phase 2Unknown

Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

Role: lead

NCT00276679Phase 2Completed

Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma

Role: lead